After establishing efficient engineering, a favorable safety profile and demonstration of preserved function and long-term engraftment potential of E51K and E51T HSPCs, we sought to investigate tumor selective CD123-targeted immunotherapy and resistance of engineered HSPCs. The gene discussed is IL3RA; the disease is neoplasm.